# Research Priorities & Roadmap 2025-2030

**Document Version**: 1.0
**Last Updated**: November 7, 2025
**Owner**: Chief Research Officer
**Purpose**: Define foundation's research strategy, funding priorities, and 5-year roadmap

---

## üìã Table of Contents

1. [Research Vision & Mission](#research-vision--mission)
2. [Current Research Landscape](#current-research-landscape)
3. [Research Priorities](#research-priorities)
4. [5-Year Research Roadmap](#5-year-research-roadmap)
5. [Funding Strategy](#funding-strategy)
6. [Research Partnerships](#research-partnerships)
7. [Grant Program Overview](#grant-program-overview)
8. [Success Metrics](#success-metrics)
9. [Governance & Oversight](#governance--oversight)

---

## Research Vision & Mission

### Vision

**"Accelerate research to cure AATD and eliminate diagnostic delays"**

We envision a future where:

- AATD is detected at birth or first symptoms
- Gene therapy cures AATD
- AAT protein therapy is affordable and accessible
- No one suffers preventable lung/liver damage
- Diagnostic delays are eliminated

---

### Mission

**Fund innovative, high-impact research that**:

- Reduces diagnostic delays
- Improves early detection methods
- Advances treatment options
- Works toward a cure
- Repurposes AAT protein for other conditions

---

### Research Philosophy

**1. Patient-Centered**:

- Research priorities driven by patient needs
- Patients involved in research design and oversight
- Focus on improving quality of life

**2. High-Risk, High-Reward**:

- Fund innovative, early-stage research
- Fill gaps where larger funders won't invest
- Comfortable with calculated risks

**3. Collaborative**:

- Partner with academic institutions, industry, government
- Leverage Mark's patent and expertise
- Share data and findings openly

**4. Translation-Focused**:

- Prioritize research with clear path to clinical application
- Bridge gap between discovery and patient impact
- Speed time from lab to bedside

**5. Entrepreneurial**:

- Commercialize Mark's patent to generate revenue
- Reinvest profits into more research
- Sustainable funding model

---

## Current Research Landscape

### What We Know

**AATD Basics (Well-Established)**:

- Genetic cause (SERPINA1 gene mutations)
- Inheritance pattern (autosomal codominant)
- Primary effects (emphysema, cirrhosis)
- Natural history and progression

**Current Treatments**:

- Augmentation therapy (slows but doesn't cure)
- Standard COPD management
- Liver/lung transplantation

**Diagnostic Challenges**:

- Average 7-8 year delay
- Misdiagnosis common (asthma, COPD, bronchitis)
- Low awareness among physicians
- Testing underutilized

---

### What We Don't Know (Research Gaps)

**1. Early Detection**:

- How to identify AATD patients earlier?
- Better biomarkers or screening methods?
- Point-of-care testing (AAT "glucometer")?

**2. Disease Mechanisms**:

- Why do some ZZ patients get sick and others don't?
- Genetic modifiers (other genes that affect risk)?
- Role of environmental factors (smoking, exposures)?
- Liver disease mechanisms (why only 30-40% affected)?

**3. Treatment Optimization**:

- Does augmentation therapy prevent disease (vs. just slow)?
- Optimal timing to start therapy?
- Better delivery methods (inhaled, subcutaneous)?
- Combination therapies?

**4. Cure**:

- Gene therapy feasibility and safety?
- Gene editing (CRISPR) potential?
- Stem cell approaches?

**5. Repurposing AAT**:

- Can AAT protein protect firefighters, military?
- Efficacy in asthma, COVID-19, other inflammatory diseases?
- Optimal dosing and delivery?

---

### Who Else Is Funding AATD Research?

**Alpha-1 Foundation**:

- Largest AATD research funder (~$3-5M/year)
- Focus: Disease mechanisms, treatment, quality of life
- Established player (since 1995)

**NIH (National Institutes of Health)**:

- $5-10M/year for AATD research
- Focus: Basic science, clinical trials

**Pharmaceutical Companies**:

- Grifols, CSL Behring, Takeda
- Focus: Augmentation therapy, gene therapy

**European Respiratory Society**:

- ‚Ç¨1-2M/year
- Focus: European research collaborations

**Mark Egly Foundation's Niche**:

- **Diagnostic delay reduction** (underserved area)
- **Innovation & commercialization** (Mark's patent, AAT glucometer)
- **Repurposing research** (firefighters, military, asthma)
- **High-risk pilot projects** (seed funding for novel ideas)

---

## Research Priorities

### Priority 1: Reducing Diagnostic Delays (40% of research budget)

**Goal**: Cut diagnostic delays from 7-8 years to 3-4 years by 2030

**Research Areas**:

**A. Early Detection Tools**:

- Point-of-care AAT testing device (AAT "glucometer")
- Rapid genotype testing (fingerstick ‚Üí results in minutes)
- Integration into routine screening (like cholesterol test)

**B. Physician Education Research**:

- Evaluate effectiveness of CME programs
- Barriers to AATD testing (physician surveys)
- Interventions to increase testing rates

**C. Clinical Decision Support**:

- EMR alerts for high-risk patients (e.g., "COPD age <45 ‚Üí test for AATD")
- AI/machine learning to identify undiagnosed cases

**D. Newborn Screening**:

- Pilot programs in select states
- Cost-effectiveness analysis
- Long-term follow-up of identified cases

---

### Priority 2: Novel Treatments & Cure (30% of research budget)

**Goal**: Advance therapies toward FDA approval; support gene therapy research

**Research Areas**:

**A. Gene Therapy**:

- Support Phase 1/2 clinical trials
- Long-term safety and efficacy data
- Optimize vector design and delivery

**B. Inhaled Augmentation Therapy**:

- Phase 3 trial support
- Patient preference studies
- Cost-effectiveness analysis

**C. Neutrophil Elastase Inhibitors**:

- Small molecule drugs to block elastase
- Alternative to AAT replacement

**D. Preventive Therapy**:

- Start augmentation therapy BEFORE lung damage?
- Clinical trials in asymptomatic ZZ patients

**E. Personalized Medicine**:

- Genetic modifiers (why some ZZ patients do better?)
- Biomarkers to predict disease progression
- Tailor treatment to individual risk

---

### Priority 3: Repurposing AAT Protein (20% of research budget)

**Goal**: Expand AAT protein use beyond AATD ‚Üí new revenue streams

**Research Areas**:

**A. Firefighter Protection**:

- Does prophylactic AAT prevent smoke inhalation injury?
- Dose-finding studies
- Clinical trial in firefighters exposed to smoke

**B. Military Applications**:

- AAT for burn pit exposure
- PTSD/TBI (anti-inflammatory effects?)
- Deployment preparedness

**C. Asthma Treatment**:

- AAT as add-on therapy for severe asthma
- Mechanism studies
- Phase 2 clinical trial

**D. Other Inflammatory Diseases**:

- COVID-19 and acute respiratory distress
- Autoimmune diseases (vasculitis, rheumatoid arthritis)
- Liver disease (NASH, cirrhosis)

**Why This Matters**:

- Repurposing = huge market (millions vs. thousands)
- Revenue from Mark's patent (US20220160847) funds more AATD research
- More AAT production ‚Üí lower costs for AATD patients

---

### Priority 4: Mass Production & Accessibility (5% of research budget)

**Goal**: Lower cost of AAT protein; increase global access

**Research Areas**:

**A. Novel Production Methods**:

- Recombinant AAT (bacteria, yeast, mammalian cells)
- Transgenic animals (AAT from milk, blood)
- Plant-based production

**B. Cost Reduction**:

- Currently $100K-$200K/year per patient
- Goal: <$50K/year
- Makes treatment accessible in low-income countries

**C. Formulation Optimization**:

- Extended half-life (less frequent dosing)
- Subcutaneous delivery (vs. IV)
- Oral formulations (if possible)

---

### Priority 5: Understanding Disease Mechanisms (5% of research budget)

**Goal**: Fill knowledge gaps to inform treatment development

**Research Areas**:

**A. Genetic Modifiers**:

- Why do some ZZ patients never get sick?
- Genome-wide association studies (GWAS)
- Protective genetic variants

**B. Liver Disease Mechanisms**:

- Why only 30-40% of ZZ adults develop liver disease?
- Role of polymerized AAT (aggregates in liver cells)
- Therapies to clear aggregates

**C. Lung-Liver Connection**:

- Do patients with liver disease progress faster?
- Interactions between organs

**D. Environmental Factors**:

- Specific exposures that accelerate disease (beyond smoking)
- Occupational hazards
- Air pollution effects

---

## 5-Year Research Roadmap

### Year 1 (2026): Foundation & Pilot Projects ($200K research budget)

**Q1-Q2: Establish Research Program**:

- Hire Chief Research Officer
- Form Scientific Advisory Board (5-7 experts)
- Develop grant application process and criteria
- Launch research website/portal

**Q3-Q4: Fund Pilot Projects**:

- Issue first RFA (Request for Applications)
- Focus: Diagnostic delay reduction
- 3-5 pilot grants ($25K-$50K each)
- Examples:
  - EMR-based clinical decision support tool
  - Physician survey on AATD testing barriers
  - Point-of-care testing device feasibility

**Commercialization Groundwork**:

- Patent analysis and freedom to operate
- Identify potential licensees/partners
- Preliminary market research

---

### Year 2 (2027): Expand Portfolio ($500K research budget)

**Research Grants**:

- 5-10 pilot grants ($25K-$75K each)
- Expanded focus: Diagnostic delays, repurposing, treatment

**Priority Projects**:

- **AAT "Glucometer" Development**: Partner with device company, fund Phase 1 prototype
- **Firefighter Study**: Pilot trial (N=50) of prophylactic AAT in firefighters
- **CME Effectiveness Study**: Evaluate impact of AATD education on testing rates

**Partnerships**:

- Initiate discussions with pharmaceutical companies (Grifols, CSL Behring)
- Collaborate with Alpha-1 Foundation (co-fund projects)
- Engage academic medical centers (Johns Hopkins, Mayo, National Jewish)

---

### Year 3 (2028): Scaling & Clinical Trials ($1M research budget)

**Research Grants**:

- 10-15 grants ($50K-$150K each)
- Mix of pilot and larger projects

**Priority Projects**:

- **AAT Glucometer Phase 2**: Clinical validation (N=500), FDA discussions
- **Firefighter Phase 2 Trial**: Larger study (N=200), multi-site
- **Gene Therapy Support**: Co-fund Phase 2 trial with industry partner
- **Newborn Screening Pilot**: Partner with 1-2 states, screen 50K babies

**Commercialization Progress**:

- License Mark's patent to pharmaceutical company or develop in-house
- Revenue projections and business plan
- Reinvest early profits into research

---

### Year 4 (2029): Translation & Scale ($1.5M research budget)

**Research Grants**:

- 15-20 grants ($50K-$200K each)
- Emphasis on translation (bench to bedside)

**Priority Projects**:

- **AAT Glucometer Phase 3**: FDA pivotal trial, commercialization path
- **Firefighter Phase 3 Trial**: Definitive efficacy study, FDA approval track
- **Inhaled AAT**: Co-fund Phase 3 trial (if promising)
- **AI-Based Diagnostic Tool**: Machine learning to identify undiagnosed AATD in EMRs

**Revenue Generation**:

- Patent licensing revenue: $1-5M (projected)
- Royalties from AAT glucometer sales
- Reinvest into research

---

### Year 5 (2030): Established Leader ($2M+ research budget)

**Research Grants**:

- 20-30 grants ($50K-$250K each)
- Full portfolio: Diagnostic delays, treatment, cure, repurposing

**Priority Projects**:

- **AAT Glucometer Commercialization**: Device on market, widespread use
- **Firefighter Treatment**: FDA approval (if successful), rollout to fire departments nationwide
- **Gene Therapy Follow-Up**: Long-term safety/efficacy data, support FDA approval
- **Newborn Screening Expansion**: 5-10 states, 200K+ babies screened

**Impact**:

- Diagnostic delays measurably reduced (7-8 years ‚Üí 4-5 years)
- New treatments in pipeline or approved
- Foundation recognized as leading AATD research funder
- Sustainable revenue from commercialization

---

## Funding Strategy

### Research Budget Allocation (5-Year Total: ~$5.2M)

| Year | Research Budget | % of Total Budget |
| ---- | --------------- | ----------------- |
| 2026 | $200,000        | 40%               |
| 2027 | $500,000        | 33%               |
| 2028 | $1,000,000      | 30%               |
| 2029 | $1,500,000      | 30%               |
| 2030 | $2,000,000      | 29%               |

**Grant Sizes**:

- **Pilot Grants**: $25,000-$50,000 (1 year)
- **Standard Grants**: $50,000-$150,000 (1-2 years)
- **Major Grants**: $150,000-$250,000 (2-3 years)

---

### Funding Sources

**Year 1-2 (Startup Phase)**:

- Individual donations: 60%
- Foundation grants: 30%
- Special events: 10%

**Year 3-4 (Growth Phase)**:

- Individual donations: 40%
- Foundation grants: 30%
- Corporate partnerships: 20%
- Patent revenue: 10%

**Year 5+ (Sustainability)**:

- Individual donations: 30%
- Foundation grants: 20%
- Corporate partnerships: 20%
- Patent/commercialization revenue: 30%

**Goal**: Achieve financial sustainability through commercialization revenue

---

## Research Partnerships

### Academic Institutions

**Target Partners**:

- **National Jewish Health** (Denver): Leading AATD research center
- **Johns Hopkins University**: Genetic research, clinical trials
- **Mayo Clinic**: Clinical care and research
- **University of Florida**: Transplant expertise, AATD clinic
- **UCSF**: Gene therapy research
- **Cleveland Clinic**: Clinical protocols, large patient population

**Partnership Models**:

- Co-fund research projects (50/50 split)
- Provide patient recruitment support
- Data sharing agreements
- Collaborative grant applications (NIH, ALA)

---

### Industry Partners

**Pharmaceutical Companies**:

- **Grifols, CSL Behring, Takeda**: Augmentation therapy manufacturers
  - Co-develop inhaled AAT
  - License Mark's patent for repurposing research
  - Data sharing (post-market surveillance)

- **Gene Therapy Companies**: Arrowhead, Generation Bio, etc.
  - Co-fund clinical trials
  - Patient advocacy and enrollment support

**Device Companies**:

- Partner to develop AAT glucometer
- Co-fund FDA trials
- Licensing agreements

**Genetic Testing Companies**:

- 23andMe, AncestryDNA, Invitae
- Integrate AATD awareness into consumer reports
- Direct-to-consumer testing partnerships

---

### Government & Foundations

**NIH (National Institutes of Health)**:

- Co-fund large studies (NIH typically requires non-federal match)
- Leverage foundation funds to secure NIH grants

**CDC (Centers for Disease Control)**:

- Newborn screening pilots
- Public health surveillance data

**Alpha-1 Foundation**:

- Co-fund high-priority projects
- Avoid duplication, maximize impact
- Joint symposia and conferences

**American Lung Association, CHEST Foundation**:

- Co-sponsor research grants
- Joint educational initiatives

---

## Grant Program Overview

### Types of Grants

**1. Pilot Grants ($25K-$50K, 1 year)**:

- Novel ideas, early-stage research
- Preliminary data for larger grants
- Quick turnaround (3-month review)

**2. Standard Research Grants ($50K-$150K, 1-2 years)**:

- Well-defined projects with clear milestones
- Established investigators or collaborative teams
- Annual review and reporting

**3. Major Impact Grants ($150K-$250K, 2-3 years)**:

- High-impact, transformative projects
- Multi-site or clinical trials
- Detailed oversight and governance

**4. Innovation Awards ($50K-$100K, 1-2 years)**:

- High-risk, high-reward research
- Entrepreneurial projects (commercialization potential)
- Flexible milestones

---

### Research Focus Areas (Priority Ranking)

**Tier 1 (Highest Priority)**:

- Early detection and diagnostic delay reduction
- AAT glucometer development
- Repurposing research (firefighters, military)

**Tier 2 (High Priority)**:

- Gene therapy and cure research
- Novel treatments (inhaled AAT, elastase inhibitors)
- Newborn screening

**Tier 3 (Moderate Priority)**:

- Disease mechanisms and biomarkers
- Quality of life research
- Cost-effectiveness studies

---

### Application Process

**Annual Cycle**:

- **January**: RFA (Request for Applications) issued
- **April**: Letters of intent (LOI) due (2-page concept)
- **May**: LOIs reviewed, select for full application
- **July**: Full applications due
- **September**: Scientific Advisory Board review
- **October**: Funding decisions announced
- **November-December**: Award negotiations, contracting
- **January**: Research begins

**Rolling Applications** (Innovation Awards only):

- Apply anytime
- Faster review (6 weeks)

---

### Review Criteria

**Scientific Merit (40%)**:

- Innovation and significance
- Research design and methods
- Feasibility

**Alignment with Priorities (30%)**:

- Addresses foundation's research priorities
- Patient impact potential
- Path to clinical translation

**Investigator Qualifications (15%)**:

- Track record and expertise
- Team composition
- Institutional support

**Budget & Value (15%)**:

- Cost-effectiveness
- Justification of expenses
- Leverage (other funding sources)

---

## Success Metrics

### Research Output Metrics

**Publications**:

- Number of peer-reviewed papers from funded projects
- High-impact journals (e.g., NEJM, Lancet, AJRCCM)
- Goal: 10-15 publications per year by Year 5

**Presentations**:

- Conference abstracts and talks (ATS, CHEST, ERS)
- Goal: 20-30 presentations per year by Year 5

**Patents & IP**:

- New patents filed from funded research
- Licensing agreements

---

### Translation Metrics

**Clinical Trials**:

- Number of Phase 1/2/3 trials supported
- FDA approvals (treatments, devices)
- Goal: 1-2 FDA approvals by Year 5

**Clinical Guidelines**:

- Foundation-funded research cited in ATS/ERS guidelines
- Practice changes resulting from research

**Commercialization**:

- Products brought to market (AAT glucometer, repurposed AAT)
- Revenue generated

---

### Patient Impact Metrics

**Diagnostic Delay Reduction**:

- Average time from symptom onset to diagnosis
- Baseline: 7-8 years (2025)
- Goal: 3-4 years (2030)

**Testing Rates**:

- % of COPD patients tested for AATD
- Baseline: ~10% (2025)
- Goal: >50% (2030)

**Treatment Access**:

- Number of patients receiving augmentation therapy
- Baseline: 7,000 (2025)
- Goal: 15,000 (2030)

---

### Financial Metrics

**Funding Leverage**:

- Total research funded vs. foundation investment
- Goal: 2:1 leverage (foundation $1 ‚Üí $2 total research)

**Commercialization Revenue**:

- Patent licensing income
- Royalties from devices/products
- Goal: $5-10M cumulative by Year 5

**Return on Investment**:

- Patient lives saved or improved per dollar invested
- Cost per QALY (quality-adjusted life year)

---

## Governance & Oversight

### Scientific Advisory Board (SAB)

**Composition** (7-9 members):

- AATD physician-researchers (pulmonologists, hepatologists)
- Basic scientists (geneticists, molecular biologists)
- Patient representatives (2)
- Industry representative (pharmaceutical or device)
- Biostatistician/epidemiologist

**Responsibilities**:

- Review grant applications
- Advise on research priorities
- Monitor funded projects
- Provide strategic guidance

**Meetings**: Quarterly (virtual), Annual in-person retreat

---

### Research Committee (Board-Level)

**Composition**: 3-4 board members + Chief Research Officer

**Responsibilities**:

- Approve research budget and priorities
- Oversee SAB
- Review major grant decisions
- Monitor progress on research goals

**Meetings**: Quarterly

---

### Ethics & Integrity

**Principles**:

- All research must be IRB-approved
- Data transparency and sharing (within HIPAA limits)
- No conflicts of interest (disclosed and managed)
- Patient privacy and consent

**Compliance**:

- Annual ethics training for staff
- Grant agreements include ethics clauses
- Monitor for research misconduct

---

## Summary: Our Research Impact

**By 2030, we aim to**:

- ‚úÖ Fund 100+ research projects ($5M+ invested)
- ‚úÖ Reduce diagnostic delays by 50% (7-8 years ‚Üí 3-4 years)
- ‚úÖ Support FDA approval of new treatments/devices
- ‚úÖ Generate revenue from Mark's patent and AAT glucometer
- ‚úÖ Establish Mark Egly Foundation as leading AATD research funder

**Our unique niche**:

- Diagnostic delay reduction (underserved)
- Innovation and commercialization (entrepreneurial)
- Repurposing research (expands impact beyond AATD)
- High-risk, high-reward projects (fill gaps)

**We don't just fund research‚Äîwe accelerate cures.**

---

**Questions or Research Ideas?**

**Mark Egly Foundation**
üìß Email: research@markeglyfoundation.org
üåê Website: MarkEglyFoundation.org/research

---

**Approved by**: Scientific Advisory Board & Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Funding today's research to cure tomorrow's patients."_

**‚Äî Mark Egly Foundation**
